Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
MedPage Today

'Amazing' Results With Methotrexate for Retinal Detachment Repair

LONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early results in preventing proliferative vitreoretinopathy (PVR), according to ...
New Atlas

Injectable antibodies in nanoparticles could replace hour-long infusions

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...
WebMD

Your Guide to Ocrevus and Ocrevus Zunovo for Multiple Sclerosis (MS)

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Home Administration Models, Compounding Standards, and What Consumers Should Know Before Choosing a Telehealth NAD+ Provider ...
Medscape

Monoclonal Antibodies for COVID – Give IV Infusion or an Injection?

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New research suggests that the casirivimab-imdevimab monoclonal antibody treatment for COVID-19 ...